IRIS
TACCONELLI, Stefania
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.381
EU - Europa 3.271
AS - Asia 2.259
SA - Sud America 203
AF - Africa 30
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 5
Totale 9.155
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.347
CN - Cina 882
SG - Singapore 786
UA - Ucraina 528
IE - Irlanda 507
IT - Italia 500
GB - Regno Unito 389
SE - Svezia 354
TR - Turchia 351
FR - Francia 332
DE - Germania 225
BR - Brasile 194
FI - Finlandia 135
PL - Polonia 108
RU - Federazione Russa 96
IN - India 89
HK - Hong Kong 34
CZ - Repubblica Ceca 27
SA - Arabia Saudita 25
BE - Belgio 23
VN - Vietnam 19
CA - Canada 15
MX - Messico 15
AT - Austria 14
BD - Bangladesh 13
ZA - Sudafrica 12
JP - Giappone 11
AE - Emirati Arabi Uniti 10
NL - Olanda 10
IQ - Iraq 8
IR - Iran 7
ES - Italia 6
EU - Europa 5
LY - Libia 5
AR - Argentina 4
AU - Australia 4
BY - Bielorussia 4
EG - Egitto 4
LT - Lituania 4
MA - Marocco 4
GR - Grecia 3
IL - Israele 3
PK - Pakistan 3
AZ - Azerbaigian 2
EC - Ecuador 2
ID - Indonesia 2
OM - Oman 2
PH - Filippine 2
PS - Palestinian Territory 2
RO - Romania 2
TH - Thailandia 2
UZ - Uzbekistan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
BN - Brunei Darussalam 1
CG - Congo 1
CH - Svizzera 1
CO - Colombia 1
DM - Dominica 1
DZ - Algeria 1
EE - Estonia 1
GA - Gabon 1
GT - Guatemala 1
HN - Honduras 1
JM - Giamaica 1
JO - Giordania 1
KE - Kenya 1
KZ - Kazakistan 1
NO - Norvegia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
TN - Tunisia 1
UY - Uruguay 1
VE - Venezuela 1
Totale 9.155
Salva come PNG Salva come JPEG
Città #
Chandler 662
Jacksonville 583
Singapore 553
Dublin 498
Southend 312
Princeton 220
Beijing 199
Dearborn 182
Izmir 170
Nanjing 155
Ashburn 142
Wilmington 101
Kraków 98
Cambridge 96
Tongling 84
Chieti 83
Altamura 79
The Dalles 71
Ann Arbor 67
Nanchang 64
Santa Clara 56
Boardman 53
Munich 50
Los Angeles 44
Shenyang 42
Woodbridge 38
Hong Kong 34
Council Bluffs 33
Hebei 29
Changsha 28
Grevenbroich 27
Hefei 27
New York 27
Pescara 27
Helsinki 25
Jiaxing 23
Brno 22
Riyadh 22
Tianjin 22
Kocaeli 21
Washington 21
Brussels 20
Kunming 20
Camerino 19
Seattle 19
São Paulo 19
Orange 17
Shanghai 17
Hangzhou 16
Spoltore 16
Norwalk 15
Nuremberg 14
Chicago 12
Düsseldorf 12
Rome 12
Brooklyn 11
Jinan 11
Leawood 11
Lanzhou 10
Lappeenranta 10
Dong Ket 9
Guangzhou 9
Warsaw 9
Augusta 8
Houston 8
Montesilvano 8
Romola 8
Turku 8
Vienna 8
Boston 7
Cape Town 7
Menlo Park 7
Mexico City 7
Belo Horizonte 6
Brasília 6
Charlotte 6
Dubai 6
Fuzhou 6
L’Aquila 6
Mumbai 6
Ningbo 6
Rio de Janeiro 6
San Francisco 6
San Mateo 6
Silvi 6
Simi Valley 6
Amsterdam 5
Ankara 5
Atlanta 5
Auburn Hills 5
Frankfurt am Main 5
Moscow 5
Olomouc 5
Padova 5
Perm 5
Taizhou 5
Tavagnacco 5
Changchun 4
Hanoi 4
Johannesburg 4
Totale 5.619
Salva come PNG Salva come JPEG
Nome #
“DERIVATI ISOSSAZOLICI E LORO IMPIEGO COME INIBITORI DELLA CICLOOSSIGENASI” 205
Low-dose aspirin acetylates cyclooxygenase-1 in human colorectal mucosa: implications for the chemoprevention of colorectal cancer. 136
ROLE OF DOSE POTENCY IN THE PREDICTION OF RISK OF MYOCARDIAL INFARCTION ASSOCIATED WITH NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN THE GENERAL POPULATION. 123
Response to "Pharmacodynamic Interaction Between Aspirin and Ibuprofen: A Plausible Mechanism of Aspirin Resistance" 122
Reduced variability to aspirin antiplatelet effect by the coadministration of statins in high-risk patients for cardiovascular disease. 122
Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action 118
The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity. 117
Dysregulated post-transcriptional control of COX-2 gene expression in gestational diabetic endothelial cells 115
Nonsteroidal anti-inflammatory drugs and cardiovascular safety - translating pharmacological data into clinical readouts. 113
Platelet-specific deletion of cyclooxygenase-1 ameliorates dextran sulfate sodium-induced colitis in mice. 109
Antithrombotic Agents and Cancer 107
Effects of AF3442 [N-(9-ethyl-9H-carbazol-3-yl)-2-(trifluoromethyl)benzamide], a novel inhibitor of human microsomal prostaglandin E synthase-1, on prostanoid biosynthesis in human monocytes in vitro. 105
Oxidative stress and platelet activation in essential hyperytension 103
THE SELECTIVITY OF NOVEL COX-2 INHIBITORS IN HUMAN WHOLE BLOOD ASSAYS OF COX-ISOZYME ACTIVITY. 103
New insights into COX-2 biology and inhibition. 102
Reduced thromboxane biosynthesis in carriers of toll-like receptor 4 polymorphisms in vivo. 101
Measurement of 8-iso-prostaglandin F2alpha in biological fluids as a measure of lipid peroxidation 101
Platelet activation in patients with colorectal cancer. 100
miR-574-5p as RNA decoy for CUGBP1 stimulates human lung tumor growth by mPGES-1 induction. 100
Grand challenges in pharmacotherapy of inflammation for the first decades of the 21st century. 100
Modulation of prostaglandin h synthase-2 (pghs-2) expression in human monocytes by glucocorticoids. 99
PROSTAGLANDIN E2-MEDIATED ACTIVATION OF PHOSPHATIDYLINOSITOL 3-OH KINASE DIFFERENTIALLY AFFECTS IL-10 AND IL-1β PRODUCTION IN BLOOD CELLS. 98
Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences 98
Mechanisms of the antitumoural effects of aspirin in the gastrointestinal tract. 98
ISOXAZOLE DERIVATIVES AND THEIR USE AS CYCLOOXYGENASE INHIBITORS 97
The future of traditional nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors in the treatment of inflammation and pain. 96
Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. 95
Effects of estrogen on endothelial prostanoid production and cyclooxygenase-2 and heme oxygenase-1 expression. 94
CYCLOOXYGENASE-2-DERIVED PROSTACYCLIN RESTRAIN PLATELET THROMBOXANE BIOSYNTHESIS IN TOLL-LIKE RECEPTOR 4 POLYMORPHISM 93
Effects of Acetaminophen on Constitutive and Inducible Prostanoid Biosynthesis in Human Blood Cells in vitro 92
Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease 92
OXIDATIVE STRESS AND PLATELET ACTIVATION IN HUMAN ESSENTIAL HYPERTENSION. 91
Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor. 91
Mechanistic and pharmacological issues of aspirin as an anticancer agent 91
Clinical pharmacology of selective COX-2 inhibitors. 90
Synthesis, pharmacological characterization, and docking analysis of a novel family of diarylisoxazoles as highly selective cyclooxygenase-1 (COX-1) inhibitors. 90
“ISOXAZOLE DERIVATIVES AND THEIR USE AS CYCLOOXYGENASE INHIBITORS" 87
Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease 87
Effects of celecoxib on prostanoid biosynthesis and circulating angiogenesis proteins in familial adenomatous polyposis. 87
Pharmacodynamic of cyclooxygenase inhibitors in humans. 86
The human pharmacology of monocyte cyclooxygenase 2 inhibition by cortisol and synthetic glucocorticoids. 86
Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. 86
LOW-DOSE NAPROXEN INTERFERES WITH THE ANTIPLATELET EFFECT OF LOW-DOSE ASPIRIN IN HEALTHY SUBJECTS. 85
Clinical pharmacology of novel selective COX-2 inhibitors. 85
INIBITORI SELETTIVI DI COX-2: LE NUOVE MOLECOLE 85
Cardiovascular effects of valdecoxib: transducing human pharmacology results into clinical read-outs. 85
Pharmacological Characterization of the Microsomal Prostaglandin E2 Synthase-1 Inhibitor AF3485 In Vitro and In Vivo 85
Dose- Dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. 84
EFFECTS OF CELECOXIB ON SYSTEMIC MARKERS OF PROSTANOID GENERATION AND INFLAMMATION AND ANGIOGENESIS IN PATIENTS WITH FAMILIAL ADENOMATOUS POLYPOSIS: A BIOMARKER CLINICAL STUDY. 84
Altered release of cytochrome p450 metabolites of arachidonic acid in renovascular disease. 84
Gut microbiota, host gene expression, and aging. 84
CLINICAL PHARMACOLOGY OF CYCLOOXYGENASE INHIBITION BY NAPROXEN AND LOW-DOSE ASPIRIN. 83
De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin. 83
“DIARILISOSSAZOLI FUNZIONALIZZATI INIBITORI DELLA CICLOSSIGENASI” 82
Incomplete suppression of platelet COX-1 activity associated with aspirin-resistant thromboxane biosynthesis in acute coronary syndromes 82
Clinical pharmacology of cyclooxygenase inhibition and pharmacodynamic interaction with aspirin by floctafenine in Thai healthy subjects. 82
Variability in the Response to Non-Steroidal Anti-Inflammatory Drugs: Mechanisms and Perspectives. 81
Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects 80
Aspirin-triggered lipoxin in patients treated with aspirin and selective vs. non-selective COX-2 inhibitors 80
NSAIDs and cardiovascular disease. 80
Risk management profile of etoricoxib: An example of personalized medicine 80
Determinants of platelet activation in human essential hypertension. 79
Reduced thromboxane biosynthesis in carriers of Toll-like receptor 4 polymorphisms in vivo 78
P2Y12 Receptors in Tumorigenesis and Metastasis 78
NSAIDs and cardiovascular disease: transducing human pharmacology results into clinical read-outs in the general population. 77
Celecoxib, ibuprofen and the antiplatelet effect of aspirin in patients with osteoarthritis and chronic stable angina 77
Clinical pharmacology of etoricoxib. 76
Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects 76
Characterization of cyclooxygenase-2 acetylation and prostanoid inhibition by aspirin in cellular systems 76
Enhanced thromboxane biosynthesis in patients with colorectal and lung cancer 75
Novel synthesis of 3,4-diarylisoxazole analogues of valdecoxib: reversal cyclooxygenase-2 selectivity by sulfonamide group removal. 74
INHIBITION OF INDUCILE CYCLOOXYGENASE ACTIVITY BY GLUCOCORTICOIDS IN MAN. 73
DIFFERENTIAL ASSOCIATION BETWEEN HUMAN PROSTACYCLIN RECEPTOR POLYMORPHISMS AND THE DEVELOPMENT OF VENOUS THROMBOSIS AND INTIMAL HYPERPLASIA: A CLINICAL BIOMARKER STUDY. 73
CLINICAL PHARMACOLOGY OF PLATELET COX INHIBITION BY NAPROXEN AND LOW-DOSE ASPIRIN. 72
Functionalized diarylisoxazoles inhibitors of ciclooxygenase 72
EFFECTS OF ACETAMINOPHEN ON CONSTITUTIVE AND INDUCIBLE PROSTANOID BIOSYNTHESIS IN HUMAN BLOOD CELLS. 71
INCREASED OXIDATIVE STRESS IN RENOVASCULAR HYPERTENSION. 71
ENHANCED CORTISOL SECRETION DOES NOT CONTROL ASPIRIN-INSENSITIVE THROMBOXANE BIOSYNTHESIS IN PATIENTS WITH ACUTE CORONARY SYNDROMES 71
Effects of vitamin E supplementation on F2-isoprostane and thromboxane biosynthesis in healthy cigarette smokers. 71
Human pharmacology of naproxen sodium. 71
EFFECTS OF ACETAMINOPHEN ON CONSTITUTIVE AND INDUCILE PROSTANOID BIOSYNTHESIS IN HUMAN BLOOD CELLS IN VITRO. 70
ISOPROSTANES: ARE THEY MORE THAN PHYSIOPATHOLOGICAL BIOMARKERS OF LIPID PEROXIDATION? RESPONSE. 70
Managing the adverse effects of nonsteroidal anti-inflammatory drugs. 70
Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. 68
Differential association between human prostacyclin receptor polymorphisms and the development of venous thrombosis and intimal hyperplasia: a clinical biomarker study. 67
Parmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects 67
Aspirin-triggered lipoxin in patients treated with aspirin and selective vs. non-selective COX-2 inhibitors 66
Pharmacological characterization of the biosynthesis of prostanoids and hydroxyeicosatetraenoic acids in human whole blood and platelets by targeted chiral lipidomics analysis 66
Tumor-Educated Platelet Extracellular Vesicles: Proteomic Profiling and Crosstalk with Colorectal Cancer Cells 65
ENHANCED CORTISOL SECRETION DOES NOT CONTROL ASPIRIN-INSENSITIVE THROMBOXANE BIOSYNTHESIS IN PATIENTS WITH ACUTE CORONARY SYNDROMES. 64
OXIDANT STRESS AND PLATELET ACTIVATION IN ESSENTIAL HYPERTENSION. 64
Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. 64
The antiplatelet agent revacept prevents the increase of systemic thromboxane A2 biosynthesis and neointima hyperplasia 64
Mode of action of aspirin as a chemopreventive agent. 63
Antiplatelet Agents Affecting GPCR Signaling Implicated in Tumor Metastasis 63
Correlazione tra aumentata secrezione di cortisolo e marker di infiammazione nei pazienti con sindromi coronariche acute 62
Coxibs: pharmacology, toxicity and efficacy in cancer clinical trials. 62
null 62
Multifaceted Functions of Platelets in Cancer: From Tumorigenesis to Liquid Biopsy Tool and Drug Delivery System 61
Isoprostanes and other markers of peroxidation in atherosclerosis. 60
Totale 8.609
Salva come PNG Salva come JPEG
Categoria #
all - tutte 43.033
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43.033
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021642 0 2 107 8 69 129 29 23 51 124 47 53
2021/2022489 7 11 14 132 16 5 16 43 45 14 56 130
2022/20231.732 124 220 78 223 165 347 100 136 230 21 30 58
2023/2024808 52 31 69 25 63 225 183 23 5 19 9 104
2024/20251.792 123 272 198 43 52 98 66 141 152 98 219 330
2025/2026579 443 136 0 0 0 0 0 0 0 0 0 0
Totale 9.621